U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17NO
Molecular Weight 275.3444
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMIGAPIL

SMILES

CN(CC#C)CC1=CC2=C(OC3=C1C=CC=C3)C=CC=C2

InChI

InChIKey=QLMMOGWZCFQAPU-UHFFFAOYSA-N
InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3

HIDE SMILES / InChI

Molecular Formula C19H17NO
Molecular Weight 275.3444
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Omigapil (CGP 3466 or TCH346) is a structurally related analog of R-(-)-deprenyl that exhibits virtually no monoamine oxidase type B inhibiting activity but is neuroprotective in the picomolar concentration range. It binds to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and at subnanomolar concentrations prevent the S-nitrosylation of GAPDH, inhibit GAPDH-Siah binding and prevent the nuclear translocation of GAPDH. Omigapil demonstrated promising potential in the treatment of Parkinson's disease and motoneuron disease in animal models, however, it did not show efficacy in clinical trials. Omigapil is in development for the treatment of congenital muscular dystrophy.

CNS Activity

Curator's Comment: Omigapil (CGP 3466 or TCH346) demonstrated potential in the treatment of CNS diseases in animal models, however, it has not yet demonstrated efficacy in clinical trials.

Approval Year

Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, oral
Highest studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.781
unhealthy, ADULT
n = 105
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 105
Sources: Page: p.781
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1017
unhealthy, ADULT
n = 73
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 73
Sources: Page: p.1017
PubMed

PubMed

TitleDatePubMed
CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice.
2004 Dec
The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
2006 Feb 24
High-resolution structure of human D-glyceraldehyde-3-phosphate dehydrogenase.
2006 Mar
Patents

Sample Use Guides

Phase II/III randomized trial of TCH346 in patients with ALS: Patients were randomly assigned in a double-blind fashion to receive either placebo or one of four doses of TCH346 (1.0, 2.5, 7.5, or 15 mg/day) administered orally once daily for at least 24 weeks.
Route of Administration: Oral
In Vitro Use Guide
1 nM omigapil (CGP 3466 protects) PAJU cells from toxicity mediated by GAPDH overexpression.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:37 UTC 2023
Edited
by admin
on Fri Dec 15 16:30:37 UTC 2023
Record UNII
5V14HD0N4Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMIGAPIL
INN  
INN  
Official Name English
CGP-3466
Code English
N-(DIBENZO(B,F)OXEPIN-10-YLMETHYL)-N-METHYLPROP-2-YN-1-AMINE
Systematic Name English
omigapil [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 260508
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
NCI_THESAURUS C471
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID10171098
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
FDA UNII
5V14HD0N4Q
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
SMS_ID
100000177266
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
PUBCHEM
6419718
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL1232111
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
WIKIPEDIA
Omigapil
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
DRUG BANK
DB12879
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
NCI_THESAURUS
C97362
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
CAS
181296-84-4
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
INN
8383
Created by admin on Fri Dec 15 16:30:37 UTC 2023 , Edited by admin on Fri Dec 15 16:30:37 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY